Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

Epidemiological, familial, and twin studies indicate that non-alcoholic fatty liver disease, now
the leading cause of liver damage in developed countries, has a strong heritability. The …

Background Single-cell RNA sequencing (scRNA-seq) plays a pivotal role in our
understanding of cellular heterogeneity. Current analytical workflows are driven by …

Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver illness with
a genetically heterogeneous background that can be accompanied by considerable …

Excess liver fat, called hepatic steatosis, is a leading risk factor for end-stage liver disease
and cardiometabolic diseases but often remains undiagnosed in clinical practice because of …

Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver
disease in the world. Its pathogenesis is influenced by both environmental and genetic …

Non-alcoholic fatty liver disease (NAFLD) describes a steatotic (or fatty) liver occurring as a
consequence of a combination of metabolic, environmental, and genetic factors, in the …

Variants near the gene TRIB1 are significantly associated with several plasma lipid traits,
circulating liver enzymes, and the development of coronary artery disease in humans; …

Atherosclerosis is universally recognized as a chronic lipid-induced inflammation of the
vessel wall in response to dyslipidemia and haemodynamic stress involving dysfunction and …